



# CTAF

CALIFORNIA TECHNOLOGY  
ASSESSMENT FORUM


## **Brensocaticib for Non-Cystic Fibrosis Bronchiectasis: Public Meeting**

Thursday • September 25, 2025 • 9:00 AM – 3:00 PM PT

Virtual Meeting Agenda

Register for the Zoom Meeting [here](#)

Connect with ICER on our social media channels



<p><b>9:00 AM – 9:20 AM PT</b></p>	<p><b>Meeting Convened and Opening Remarks</b> Sarah K. Emond, MPP, President and CEO, ICER</p>
<p><b>9:20 AM – 10:00 AM PT</b></p>	<p><b>Presentation of the Clinical Evidence</b> Jason H. Wasfy, MD, MPhil, Associate Professor, Harvard Medical School Director of Outcomes Research and Cardiologist, Massachusetts General Hospital Heart Center</p>
<p><b>10:00 AM – 10:40 AM PT</b></p>	<p><b>Presentation of the Economic Model</b> Kibum Kim, PhD, MSc, Assistant Professor, Department of Pharmacy Systems, Outcomes and Policy, University of Illinois Chicago</p>
<p><b>10:40 AM – 11:00 AM PT</b></p>	<p><b>Public Comments and Discussion</b></p>
<p><b>11:00 AM – 11:50 AM PT</b></p>	<p><b>Lunch Break</b></p>
<p><b>11:50 AM – 12:50 PM PT</b></p>	<p><b>CTAF Vote on Clinical Effectiveness and Value</b> Moderator: Ralph G. Brindis, MD, MPH, MACC, FSCAI, FAHA Clinical Professor of Medicine at the University of California, San Francisco, Senior Medical Officer, External Affairs, for the American College of Cardiology National Cardiovascular Registry</p>
<p><b>12:50 PM – 1:00 PM PT</b></p>	<p><b>Break</b></p>
<p><b>1:00 PM – 2:30 PM PT</b></p>	<p><b>Policy Roundtable</b> Moderator: Sarah K. Emond, MPP, President and CEO, ICER</p>
<p><b>2:30 PM – 3:00 PM PT</b></p>	<p><b>Reflections from CTAF</b></p>
<p><b>3:00 PM PT</b></p>	<p><b>Meeting Adjourned</b></p>

ICER Staff and External Collaborators	Conflict of Interest
<p><b>Sarah K. Emond, MPP</b> President &amp; CEO, Institute for Clinical and Economic Review</p>	<p>No conflicts to disclose.</p>
<p><b>Kibum Kim, PhD</b> Assistant Professor at College of Pharmacy, Pharmacy Systems, Outcomes, and Policy, University of Illinois Chicago</p>	<p>No conflicts to disclose.</p>
<p><b>Sodam Kim, PharmD, BBA</b> PhD Candidate, College of Pharmacy, Pharmacy Systems, Outcomes, and Policy, University of Illinois Chicago</p>	<p>No conflicts to disclose.</p>
<p><b>Avery McKenna, BS</b> Research Lead, Institute for Clinical and Economic Review</p>	<p>No conflicts to disclose.</p>
<p><b>Daniel Ollendorf, PhD, MPH</b> Chief Scientific Officer and Director of Health Technology Assessment Methods and Engagement, Institute for Clinical and Economic Review</p>	<p>No conflicts to disclose.</p>
<p><b>Marie Phillips, BA</b> Health Economics Research Assistant, Institute for Clinical and Economic Review</p>	<p>No conflicts to disclose.</p>
<p><b>Marina Richardson, PhD, MSc</b> Associate Director, Health Technology Assessment Methods and Health Economics, Institute for Clinical and Economic Review</p>	<p>No conflicts to disclose.</p>
<p><b>Daniel R. Touchette, PharmD, MA</b> Professor at College of Pharmacy, Pharmacy Systems, Outcomes, and Policy, University of Illinois Chicago</p>	<p>No conflicts to disclose.</p>
<p><b>Jason H. Wasfy, MD, MPhil</b> Associate Professor at Harvard Medical School, Director of Outcomes Research, Massachusetts, General Hospital Cardiology Division Mass General Brigham</p>	<p>No conflicts to disclose.</p>

CTAF Members	Conflict of Interest
<p><b>Ralph Brindis, MD, MPH, MACC, FSCAI, FAHA</b> Clinical Professor of Medicine, University of California, San Francisco</p>	<p>Dr. Ralph Brindis holds stock options in GENinCode issued to him for consulting performed for the company. These options are not currently vested and have no value. Dr. Brindis will provide ICER with an update to the value of these stock options if they are converted to stock to ensure that the value does not exceed ICER's Policies to Manage Conflicts of Interest.</p>
<p><b>Felicia Cohn, PhD, HEC-C</b></p>	<p>No conflicts to disclose.</p>

Bioethics Director, Kaiser Permanente Orange County	
<b>Robert Collyar</b> Patient Advocate, Patient Advocates in Research	A member of Robert’s household received payment prior to this year from AstraZeneca for work on EVOLVE Early Breast Cancer Project.
<b>Paul Heidenreich, MD, MS</b> Professor, Stanford University	No conflicts to disclose.
<b>Jeffrey Hoch, MA, PhD</b> Professor, University of California, Davis	No conflicts to disclose.
<b>Jeff Klingman, MD</b> Neurologist, The Permanente Medical Group	No conflicts to disclose.
<b>Sei Lee, MD, MAS</b> Professor of Medicine, University of California, San Francisco	No conflicts to disclose.
<b>Kavita Nair, PhD</b> Professor of Neurology and Pharmacy, University of Colorado Anschutz Medical Campus	No conflicts to disclose.
<b>Kathryn Phillips, PhD</b> Professor, University of California, San Francisco	No conflicts to disclose.
<b>Rita Redberg, MD, MSc</b> Professor of Medicine, University of California, San Francisco	No conflicts to disclose.
<b>Tony Sowry, MA</b> National Patient Advocate Foundation	No conflicts to disclose.

<b>Policy Roundtable Participants</b>	<b>Conflict of Interest</b>
<b>Vicky Brown, PharmD, BCOP</b> Associate Vice President Clinical Drug Strategies, Humana Pharmacy Solutions	Dr. Brown is a full-time employee at Humana Pharmacy Solutions.
<b>Paul Dieffenbach, MD</b> Associate Physician, Pulmonary and Critical Care Medicine, Brigham and Women's Hospital; Instructor in Medicine, Harvard Medical School	No conflicts to disclose.
<b>Amy Leitman, JD</b> President, NTM Info & Research	45% of NTM Info and Research funding is received from health care companies.
<b>John Torrence</b> Patient Ambassador with the Bronchiectasis and NTM Association	The Bronchiectasis and NTM Association is a division of the COPD Foundation.
<b>Emily Tsiao, PharmD, BCPS</b> Senior Clinical Pharmacist, Trend Management Strategies and Programs, Premera Blue Cross	Dr. Tsiao is a full-time employee at Premera Blue Cross.